NCT02639026 is a Phase 1 clinical trial of Radiotherapy in Metastatic, sponsored by Abramson Cancer Center at Penn Medicine.

Who is sponsoring NCT02639026?

NCT02639026 is sponsored by Abramson Cancer Center at Penn Medicine.

What drugs are being tested in NCT02639026?

Interventions in NCT02639026: Radiotherapy, MEDI4736, Tremelimumab.

Is NCT02639026 still recruiting?

NCT02639026 is currently completed. Last updated 25 November 2025.

Last reviewed 2025-11-25 · How we verify

NCT02639026

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Completed Phase 1 Last updated 25 November 2025

What this trial tests

Phase 1 trial testing Radiotherapy in Metastatic in 53 participants. Completed in 27 June 2023.

Timeline

26 January 2016

Primary endpoint
27 June 2023

27 June 2023

Quick facts

Lead sponsor	Abramson Cancer Center at Penn Medicine
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	53
Start date	26 January 2016
Primary completion	27 June 2023
Estimated completion	27 June 2023
Sites	1 location across United States

Drugs / interventions tested

Radiotherapy — full drug profile →
MEDI4736 — full drug profile →
Tremelimumab (TREMELIMUMAB) — full drug profile →

Conditions studied

Metastatic — all drugs for Metastatic →
Melanoma — all drugs for Melanoma →
Non Small Cell Lung Cancer (NSCLC) — all drugs for Non Small Cell Lung Cancer (NSCLC) →
Breast Cancer — all drugs for Breast Cancer →

Sponsor

Abramson Cancer Center at Penn Medicine — full company profile →

Who can join

18 and older, any sex, with Metastatic or Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to determine how best to combine hypofractionated radiotherapy, MEDI4736, and tremelimumab and to determine how safe and tolerable hypofractionated radiotherapy, MEDI4736, and tremelimumab are when given together in subjects with metastatic, melanoma, non small cell lung cancer (NSCLC), breast cancer, and pancreatic cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Challenges and Opportunities for Pancreatic Cancer Immunotherapy.
Bear AS, Vonderheide RH, O'Hara MH. · · 2020 · cited 500× · PMID 32946773 · DOI 10.1016/j.ccell.2020.08.004
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.
Adamska A, Domenichini A, Falasca M. · · 2017 · cited 429× · PMID 28640192 · DOI 10.3390/ijms18071338
Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.
Balachandran VP, Beatty GL, Dougan SK. · · 2019 · cited 371× · PMID 30660727 · DOI 10.1053/j.gastro.2018.12.038
Mechanisms of immune evasion in breast cancer.
Bates JP, Derakhshandeh R, Jones L, Webb TJ. · · 2018 · cited 206× · PMID 29751789 · DOI 10.1186/s12885-018-4441-3
Radiation effects on antitumor immune responses: current perspectives and challenges.
Walle T, Martinez Monge R, Cerwenka A, Ajona D, et al · · 2018 · cited 178× · PMID 29383033 · DOI 10.1177/1758834017742575
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study.
Kamath SD, Kalyan A, Kircher S, Nimeiri H, et al · · 2020 · cited 151× · PMID 31740568 · DOI 10.1634/theoncologist.2019-0473
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.
Daniel SK, Sullivan KM, Labadie KP, Pillarisetty VG. · · 2019 · cited 148× · PMID 30931508 · DOI 10.1186/s40169-019-0226-9
The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer?
Hu ZI, McArthur HL, Ho AY. · · 2017 · cited 115× · PMID 28344743 · DOI 10.1007/s12609-017-0234-y

Verify or expand the search:

Other trials of Radiotherapy

Trials testing the same drug.

NCT07497607 — Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma · Phase 2 · not yet recruiting
NCT06813664 — ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI) · Phase 2 · not yet recruiting
NCT07339774 — Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients · Phase 2 · recruiting
NCT07353671 — Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis · Phase 2, PHASE3 · recruiting
NCT07245745 — Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer · NA · recruiting

Other recruiting trials for Metastatic

Currently open trials in the same condition.

NCT07523529 — Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06007937 — A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer · Phase 1, PHASE2 · recruiting
NCT05868226 — PRE-I-SPY Phase I/Ib Oncology Platform Program · Phase 1 · recruiting
NCT05472948 — Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix · Phase 2 · recruiting
NCT05496686 — Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma · Phase 1 · active not recruiting

Other Abramson Cancer Center at Penn Medicine trials

Trials by the same sponsor.

NCT07478848 — Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas · Phase 1 · not yet recruiting
NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07454499 — Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE) · NA · not yet recruiting
NCT07222241 — Comparing Numbing Techniques in Mohs Micrographic Surgery · NA · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02639026 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine
Last refreshed: 25 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02639026.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing